Leerink Partnrs Weighs in on Kymera Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:KYMR)

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) – Analysts at Leerink Partnrs issued their Q1 2024 EPS estimates for shares of Kymera Therapeutics in a research report issued on Monday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will post earnings of ($0.79) per share for the quarter. Leerink Partnrs currently has […]

Related Keywords

Hong Kong ,United States ,Canada ,America ,Piper Sandler ,Jeffreyw Albers ,Leerink Partnrs ,Ellen Chiniara ,Tower Research Capital ,Hong Kong Ltd ,Royal Bank ,Jpmorgan Chase Co ,Kymera Therapeutics Inc ,Nasdaq ,Morgan Stanley ,Kymera Therapeutics Company Profile ,Advisors Asset Management Inc ,Kymera Therapeutics ,Free Report ,Kymera Therapeutic ,Director Jeffrey ,Kong Ltd ,Asset Management ,Research Capital ,Get Free Report ,Kymera Therapeutics Daily ,Nasdaq Kymr ,Kymr ,Medical ,Earnings Estimates ,